Compare · ESTA vs ZBH
ESTA vs ZBH
Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESTA and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $18.00B, about 9.8x ESTA ($1.83B).
- ZBH has been more active in the news (13 items in the past 4 weeks vs 9 for ESTA).
- ZBH has more recent analyst coverage (25 ratings vs 15 for ESTA).
- Company
- Establishment Labs Holdings Inc.
- Zimmer Biomet Holdings Inc.
- Price
- -
- -
- Market cap
- $1.83B
- $18.00B
- 1M return
- -
- +0.77%
- 1Y return
- -
- -6.86%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 9
- 13
- Recent ratings
- 15
- 25
Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest ESTA
- Stifel initiated coverage on Establishment Labs with a new price target
- SEC Form 8-K filed by Establishment Labs Holdings Inc.
- Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
- Director Gillin Leslie was granted 262 shares, increasing direct ownership by 1% to 18,856 units (SEC Form 4)
- Director Schutter Edward J was granted 253 shares, increasing direct ownership by 0.14% to 178,205 units (SEC Form 4)
- Director Lewin Nicholas Sheridan was granted 389 shares, increasing direct ownership by 0.04% to 1,080,349 units (SEC Form 4)
- Director Slotkin Bryan was granted 253 shares, increasing direct ownership by 0.77% to 33,052 units (SEC Form 4)
- Director Custin Ann was granted 301 shares, increasing direct ownership by 1% to 24,626 units (SEC Form 4)
- Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
- Chief Executive Officer Caldini Filippo covered exercise/tax liability with 682 shares, decreasing direct ownership by 1% to 48,829 units (SEC Form 4) (tax liability)
Latest ZBH
- ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
- Barclays initiated coverage on Zimmer Biomet with a new price target
- Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
- SEC Form 4 filed by Zimmer Biomet Holdings Inc.
- SEC Form 3 filed by Zimmer Biomet Holdings Inc.
- SEC Form 3 filed by Zimmer Biomet Holdings Inc.
- SEC Form 4 filed by Director Farrell Michael J.
- SEC Form 4 filed by Director Hagemann Robert
- SEC Form 4 filed by Director Higgins Arthur J
- SEC Form 4 filed by Director Shapiro Louis